<DOC>
	<DOC>NCT01223456</DOC>
	<brief_summary>This post marketing surveillance study aims to monitor the safety and efficacy of ONGLYZA under conditions of actual use in patients who are diagnosed with diabetes mellitus type 2 and are prescribed ONGLYZA by their physician.</brief_summary>
	<brief_title>Safety and Efficacy Study of ONGLYZA (Saxagliptin) Under Conditions of Actual Use</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Diagnosis of Type 2 Diabetes Mellitus Prescribed Saxagliptin by patient's attending physician Known allergic or serious adverse reaction to Saxagliptin Pregnant or breastfeeding patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Saxagliptin</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>clinical practice</keyword>
</DOC>